Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

INTRODUCTION: Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn’s disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much le...

Full description

Saved in:
Bibliographic Details
Published in:Prz Gastroenterol
Main Authors: Szymanska, Edyta, Dadalski, Maciej, Grajkowska, Wieslawa, Szymanska, Sylwia, Pronicki, Maciej, Kierkus, Jaroslaw
Format: Artigo
Language:Inglês
Published: Termedia Publishing House 2016
Subjects:
Original Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360663/
https://ncbi.nlm.nih.gov/pubmed/28337236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pg.2016.64746
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items